Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis
Section snippets
Methods
We obtained deidentified information regarding all lung transplants performed in the United States between January 2003 and June 2017 from the Organ Procurement and Transplant Network database maintained by the United Network for Organ Sharing. As the outcomes in the US LAM patients undergoing LT between 1987 and 2002 have previously been published,15 we analyzed the data from January 2003 onwards. In May 2005, the United States began using the lung allocation score (LAS) system to determine
Results
A total of 138 patients underwent LT in the study period, accounting for 0.54% of all lung transplants performed in this duration (Table 1). Outcome data following LT was missing in 4 patients, and these patients were excluded from our analysis. From the remaining 134 patients, 87 patients were alive at the time of data analysis (65%), 43 patients had died (32%), and 4 patients were retransplanted (3%). Single LT (SLT) was performed in 25 of 134 patients (19%), and 109 patients underwent
Discussion
The first reported lung transplant for a woman with LAM was a combined heart–lung transplant performed in 1984.7 Since then, lung transplantation outcomes in LAM have been reported in multiple small studies with varying survival estimates (Table 4). The LT survival rates in our analysis are better than in some of the earlier reports8, 15, 17 and comparable to the more recent studies,13, 14 likely reflecting the effect of increased experience and improved peri-transplant care. The exact reasons
Conclusions
In patients with LAM undergoing LT, the median post-LT survival is 12 years with 1-, 5-, and 10-year survival rates of 94%, 73%, and 56%, respectively. The post-LT survival in patients with LAM is substantially better than in those with any other lung disease.
Disclosure statement
The authors have no conflicts of interest to disclose. This study was supported in part by Health Resources and Services Administration contract 234-2005-370011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of Department of Health and Human Services, nor does the mention of trade names of commercial products, or organizations imply endorsement by the U.S. Government.
References (31)
- et al.
The NHLBI LAM Registry. The NHLBI LAM Registry: Prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis
Chest
(2019) - et al.
Combined heart-and-lung transplantation for lymphangioleiomyomatosis
Lancet
(1984) - et al.
Lung transplantation for lymphangioleiomyomatosis: the European experience
J Heart Lung Transplant
(2009) - et al.
Lung transplantation for lymphangioleiomyomatosis: single-center Brazilian experience with no chylothorax
Transplantation Proceedings. Elsevier
(2011) - et al.
The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis
J Heart Lung Transplant
(2005) - et al.
Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis
Respir Med
(2015) - et al.
Lung transplantation for lymphangioleiomyomatosis
J Heart Lung Transplant
(2004) - et al.
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation
J Heart Lung Transplant
(2018) - et al.
Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study
Chest
(2007) - et al.
Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome
J Heart Lung Transplant
(2007)
Development of the new lung allocation system in the United States
Am J Transplant
Impact of the lung allocation score on survival beyond 1 year
Am J Transplant
Improved waitlist and transplant outcomes for pediatric lung transplantation after implementation of the lung allocation score
J Heart Lung Transplant
A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
Lymphangioleiomyomatosis—A wolf in sheep's clothing
J Clin Invest
Cited by (24)
Genetic diffuse cystic lung disease in adults
2024, Revue des Maladies RespiratoiresFrench recommendations for the diagnosis and management of lymphangioleiomyomatosis
2023, Respiratory Medicine and ResearchLung transplantation for lymphangioleiomyomatosis
2023, Revue des Maladies RespiratoiresLung transplantation for lymphangioleiomyomatosis
2023, Journal of Heart and Lung TransplantationCitation Excerpt :The most common overall cause of mortality in LTX patients with LAM is chronic allograft dysfunction (CLAD). The overall prevalence of CLAD in the LAM lung transplant population is similar to the general transplant population as well.22,78 Lung transplantation for LAM is rare, but for patients with end-stage disease, offers the best chance at improved quality and duration of life.
A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant
2022, Respiratory MedicineCitation Excerpt :As timing of transplantation in the United States and many other countries is uncertain, and because of these trial results, many lung transplantation programs have prohibited use of mTOR inhibitors while on the waiting list, in accordance with European Respiratory Society recommendations from 2010 [33]. However, the risk of decline in pulmonary function while on the waitlist following discontinuation of an mTOR inhibitor [19,29] is a cause of trepidation in the LAM patient community. Newer data in a cohort of idiopathic pulmonary fibrosis (IPF) patients enrolled in a clinical trial of everolimus who took the drug up to the time of lung transplantation showed no anastomotic complications, implying that, unlike its introduction immediately post-transplant, mTOR inhibitors may be safe to use in listed patients [31,32,34].
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management
2021, The Lancet Respiratory Medicine